Mind Medicine (NASDAQ, NEO:MNMD) appointed Francois Lilienthal, M.D., as chief commercial officer to support the advancement of the company’s clinical development programs.
Dr. Lilienthal has more than two decades of global biopharmaceutical experience and has served as a consultant for MindMed during the past six months.
Dr. Lilienthal has held several global leadership roles at Merck, leading successful global brand launches for HIV and Hepatitis C products; and served as executive director and U.S. brand leader at Tibotec, where he launched three innovative HIV brands and drove the launch of Prezista. He also was executive director and global marketing leader at Janssen Pharmaceutical, and director and global marketing leader at Bristol Myers Squibb.
In a statement, Robert Barrow, CEO of MindMed, said Dr. Lilienthal’s addition demonstrates the scale and immediacy of the opportunity MindMed sees in the brain health disorders market.
“Dr. Lilienthal’s expertise in growing businesses through successful global product launches across a range of therapeutic indications will be critical as we advance our pipeline and seek to address the massive need for novel therapies,” Mr. Barrow added.
Dr. Lilienthal said there is potential for psychedelic-derived medicine to address brain health disorders. “I look forward to working closely with the executive team as we continue conversations with the FDA and advance MindMed through its next phase of growth.”
